Recently published findings on convalescent plasma therapy on Covid-19 patients have triggered a debate over its efficacy. After the country’s largest such trial, known by the acronym PLACID, found that convalescent plasma was ineffective in arresting Covid-19, the Indian Council of Medical Research (ICMR) has been considering dropping this option from the national guidelines.
Daily Current Affairs Quiz 2020
Key-Points
Plasma is the liquid part of the blood. Convalescent plasma, extracted from the blood of patients recovering from an infection, is a source of antibodies against the infection.
The Plasma therapy involves using their plasma to help others recover. For Covid-19, this has been one of the treatment options.
The donor would have to be a documented case of Covid-19 and healthy for 28 days since the last symptoms.
While use of convalescent plasma seemed to improve resolution of shortness of breath and fatigue in patients with moderate Covid-19, this did not translate into a reduction in 28-day mortality or progression to severe disease.
The ICMR has been cautious because of the trial findings. Experts said, however, that guidelines are not necessarily binding and it is too early to dismiss convalescent plasma therapy.
